ABOUT
Healthcare improvements are confirmed through clinical trials, and the average cost of a Phase 1, 2, and 3 clinical trial is $4M, $13M, and $20M, respectively. These costs translate directly to product costs, as trial sponsors pass costs on to patients to recoup development expenses. Importantly, trial endpoints are often incompletely sensitive and comprise coarse assessments such as all-cause mortality or quality of life, which can be complicated in patient trials owing to varied disease trajectory and comorbid conditions, ultimately yielding higher enrollment volumes and associated costs. The overall purpose of Biosight is to provide affordable trial experimental solutions, with assessments titrated to intervention mechanisms of action, to improve the rigor and reduce the costs of clinical trials.
More specifically, Biosight LLC is a Tennessee-based Limited Liability Corporation which operates as a Clinical Research Organization (CRO) with specific expertise in advanced imaging acquisition strategies and analysis algorithms. The company mission is to improve clinical trial efficiency and outcomes through the incorporation of novel imaging markers of tissue physiology, which can be used to (i) refine enrollment criteria for more informed patient stratification or (ii) expand clinically meaningful endpoints to increase the likelihood of trial success. Biosight specializes in trials that require more complex imaging endpoints than simply tissue anatomy by providing tools to assess physiological constructs such as oxygen extraction, blood flow, and iron retention: metrics that may adjust prior to irreversible tissue damage and may serve as markers for disease-modifying interventions.
Biosight has contracted with major public pharmaceutical companies such as Pfizer, Alterity, Bluebird Bio, and Global Blood Therapeutics.Biosight was founded by Manus J. Donahue, MBA, PhD with the goal of improving the impact of clinical trials, and most importantly the lives of patients, by utilizing both the expertise of healthcare providers and quantitative scientists to take full advantage of the spectrum of theranostic care available today. Manus was educated at Duke University (Physics: BS; Philosophy: BA), The Johns Hopkins University School of Medicine (Biophysics: PhD), and the University of Oxford (Clinical Neurology: fellowship). Biosight staff have collectively published more than 250 peer-reviewed manuscripts and offer unique imaging and analysis solutions not offered by other commercial CROs.